LL-37 and Autoimmune Disease Research: Immune Modulation, TLR Biology and Inflammatory Biology

Research Use Only (RUO). All content on this page describes laboratory and preclinical research findings only. LL-37 is not approved for human therapeutic use. This information is intended for qualified researchers and laboratory professionals only.

Introduction: LL-37 Beyond Antimicrobial Defence

LL-37 — the only human cathelicidin antimicrobial peptide, cleaved from the 18 kDa hCAP-18 precursor — is best known for its direct antimicrobial activity through membrane disruption of bacterial, viral, and fungal pathogens. However, LL-37's immunomodulatory functions extend far beyond direct killing: it modulates dendritic cell (DC) maturation, drives plasmacytoid DC (pDC) type I interferon production, activates TLR7/8/9 signalling through nucleic acid complex formation, promotes neutrophil survival, and modulates T-cell polarisation. These immunomodulatory properties position LL-37 as a research tool with paradoxical relevance to autoimmune diseases — where it can be both pathologically elevated (driving autoimmune responses in psoriasis and lupus) and potentially regulatory (modulating excessive inflammation through FPRL1/FPR2 receptor-mediated immunomodulation).

The duality of LL-37 in autoimmune biology — pro-inflammatory in some contexts, anti-inflammatory in others — makes it a mechanistically rich research compound for investigating how innate immune peptides shape adaptive immune responses and contribute to autoimmune pathology initiation and perpetuation.

LL-37 and Psoriasis Biology: The Self-DNA TLR9 Mechanism

Psoriasis — a chronic autoimmune skin disease characterised by IL-17A/IL-23 axis-driven keratinocyte hyperproliferation and neutrophil-dominated plaques — provides the best-characterised example of LL-37 driving autoimmune pathology. The mechanism: (1) injured keratinocytes release self-DNA (normally non-immunostimulatory due to absence of methylated CpG motifs and inaccessibility to TLR9); (2) LL-37 in inflamed psoriatic skin binds self-DNA, forming LL-37/DNA complexes that resist nuclease degradation (LL-37 protects DNA from DNase I), compact into hexagonal crystalline structures visible by small-angle X-ray scattering, and are efficiently taken up by pDCs through endocytosis; (3) within pDC endosomes, LL-37/DNA complexes activate TLR9 (which normally recognises microbial unmethylated CpG DNA) and TLR7 (recognising single-stranded RNA — though LL-37/RNA complexes also form), driving massive IFN-α production by pDCs; (4) IFN-α activates myeloid DCs and promotes Th1/Th17 polarisation, establishing the adaptive autoimmune cycle.

Research tools for studying this mechanism: LL-37/DNA complex formation by fluorescence microscopy (Cy3-labelled LL-37 + FITC-labelled DNA co-localisation); SAXS characterisation of complex crystalline phase (d-spacing ~6.7 nm characteristic of LL-37/DNA hexagonal structure); TLR9 reporter assay (HEK293T-TLR9-NF-κB-luciferase) showing LL-37/DNA complex TLR9 activation vs DNA alone; IFN-α ELISA from pDC cultures stimulated with LL-37/DNA complexes; and chloroquine (endosomal acidification blocker) + DNase I (complex degradation) controls confirming endosomal TLR9 pathway dependence.

LL-37 and Systemic Lupus Erythematosus Research

SLE shares the LL-37/nucleic acid complex TLR-activation mechanism with psoriasis but involves RNA-containing complexes in addition to DNA. Neutrophil extracellular traps (NETs) — chromatin/DNA webs released by dying neutrophils during NETosis — contain LL-37 bound to nuclear DNA and RNA, forming the immunostimulatory complexes that drive pDC IFN-α production in SLE. Serum levels of LL-37/NET complexes correlate with disease activity in SLE patients, and anti-LL-37 antibodies are found in a subset of SLE patients.

LL-37 autoimmune research in SLE contexts examines: NETosis induction by LL-37 (LL-37 directly induces neutrophil NET formation through ROS-dependent mechanisms); LL-37/NET complex formation quantification (ELISA for LL-37 + MPO NET marker co-capture); IFN-α production from SLE patient pDCs stimulated with LL-37/NET fractions; TLR7/8 (RNA-recognising) vs TLR9 (DNA-recognising) pathway contributions in LL-37/nucleic acid SLE biology (using selective TLR antagonists: CpG oligonucleotide inhibitors for TLR9, R848 vs DMXAA for TLR7/8); and complement pathway activation by LL-37/DNA complexes (LL-37 activates complement C1q, potentially amplifying the autoimmune response).

FPR2/FPRL1 Anti-Inflammatory Signalling: The Regulatory Arm

LL-37's immunomodulatory biology is not exclusively pro-inflammatory. At physiological concentrations, LL-37 binds formyl peptide receptor 2 (FPR2/FPRL1/ALX receptor) — a Gi-coupled GPCR expressed on neutrophils, macrophages, DCs, and epithelial cells — producing anti-inflammatory effects: reduced LTB4 (leukotriene B4) production, reduced TNF-α secretion, promotion of efferocytosis (phagocytosis of apoptotic cells by macrophages), and inhibition of NF-κB nuclear translocation in macrophages. FPR2 is also the receptor for lipoxin A4 and annexin A1 — endogenous pro-resolution mediators — placing LL-37 in the resolution phase of inflammation biology.

The concentration-dependent duality of LL-37 — pro-inflammatory TLR-activating (TLR4 direct LPS-mimetic activation, TLR9/7 nucleic acid complex) at higher concentrations vs anti-inflammatory FPR2-mediated at lower concentrations — is a critical research consideration. Research distinguishing these arms uses: FPR2 selective agonist (WKYMVm peptide) and FPR2 antagonist (WRW₄) to isolate FPR2-mediated effects; TLR4 antagonist (TAK-242/CLI-095, eritoran) to isolate direct TLR4 activation; dose-response studies across 0.1–50 μg/mL LL-37 range; and cell-type-specific readouts (macrophage polarisation markers M1/M2 vs DC maturation markers CD80/86/MHC-II).

Rheumatoid Arthritis Research Context

LL-37 is elevated in synovial fluid and serum of rheumatoid arthritis (RA) patients, and is produced locally by synovial fibroblasts (FLS), neutrophils infiltrating synovium, and macrophages within pannus tissue. In RA, LL-37's immunomodulatory biology involves: FLS activation through P2X7R and EGFR receptor cross-activation (LL-37 transactivates EGFR through metalloprotease-mediated HB-EGF shedding), promoting FLS proliferation and IL-6/IL-8 production; neutrophil survival extension (delayed apoptosis through FPR2/PI3K/Akt and LL-37-induced mcl-1 upregulation); and complement activation in joint — LL-37 binds C1q and C3b, amplifying complement-mediated inflammation.

RA research model endpoints for LL-37 biology: collagen-induced arthritis (CIA) mouse model — clinical score (paw swelling, redness, mobility), histological arthritis score (synovial hyperplasia, pannus, cartilage/bone erosion by H&E and toluidine blue), anti-CII antibody titre, cytokine profiling (TNF-α, IL-6, IL-17A, IL-1β); FLS invasion assay (Matrigel invasion chamber); FLS proliferation (BrdU/Ki-67); RANKL:OPG ratio in FLS (osteoclastogenic potential); and LL-37 protein in synovial fluid by ELISA.

Inflammatory Bowel Disease and LL-37 Research

In IBD (Crohn's disease and ulcerative colitis), LL-37 shows a complex pattern: expression is paradoxically reduced in intestinal mucosa despite elevated inflammation — a finding suggesting that reduced LL-37 may contribute to impaired antimicrobial defence and dysbiosis that perpetuates IBD. However, in established inflammation, LL-37 may amplify the TLR-activated innate immune response through bacterial DNA/RNA complex formation. Research in DSS colitis models with LL-37 knockout mice vs wild-type, and with recombinant LL-37 supplementation, examines whether restoring LL-37 in the mucosal barrier is net protective (antimicrobial/barrier repair) or net pathological (TLR-driven inflammation amplification) in IBD contexts — a question with direct implications for understanding hCAP-18 biology in intestinal immunity.

Type 1 Diabetes and Innate Immune TLR Biology

Type 1 diabetes (T1D) involves autoimmune destruction of pancreatic β-cells by self-reactive T-cells. LL-37 is produced by islet cells and modulates innate immune responses in the pancreatic microenvironment. Research questions: does LL-37 from damaged islet cells form complexes with islet β-cell nuclear material, activating pDC TLR9/IFN-α pathways that prime islet-specific T-cell activation? Non-obese diabetic (NOD) mouse T1D research model with LL-37 administration examines effects on insulitis progression (islet inflammatory infiltrate), IFN-α in pancreatic lymph nodes, and β-cell survival (insulin/C-peptide area in islets).

Research Endpoint Summary

A comprehensive LL-37 autoimmune research endpoint panel includes: LL-37/DNA complex formation (SAXS, Cy3/FITC co-localisation microscopy); TLR9 reporter HEK293T activation; pDC IFN-α production (ELISA, ELISpot); NETosis quantification (SYTOX Green/MPO NET ELISA); FPR2 dose-response (WRW₄ antagonist control); macrophage NF-κB activation (p65 nuclear translocation); CIA clinical/histological score; FLS proliferation/invasion; cytokine multiplex (TNF-α/IL-6/IL-17A/IL-1β/IFN-α); complement C1q binding; TLR4/7/9 pharmacological dissection controls; and tissue LL-37 localisation (IHC in biopsy/model tissue).

Summary

LL-37 occupies a paradoxical position in autoimmune disease research: it drives psoriasis and SLE pathology through self-nucleic acid/TLR9 complex-mediated pDC IFN-α production, while simultaneously possessing FPR2-mediated pro-resolution and anti-inflammatory signalling capacity. RA, IBD, and T1D research contexts extend LL-37 autoimmune biology into synovial, intestinal, and pancreatic settings respectively. The concentration-dependent duality, cell-type-specific receptor profile (TLR4/7/9 vs FPR2), and nucleic acid complex formation biology provide rich mechanistic research questions distinct from LL-37's established direct antimicrobial function.

Research Use Only. Not for human therapeutic administration. All research must comply with applicable institutional and regulatory requirements.